Timo Roine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Timo Roine has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
- Risto Juhani Ilmoniemi
Aalto University
14 shared publications - Dogu Baran Aydogan
A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
8 shared publications - Ida Granö
Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo, Finland
8 shared publications - Pantelis Lioumis
Aalto University
8 shared publications - Alexander Leemans
Image Sciences Institute, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
7 shared publications - Ulrika Roine
Department of Pediatric Neurology, Children's Hospital, University of Helsinki and Helsinki, University Hospital, Helsinki, Finland; HUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Springer Nature in Communications Biology
Automated and noninvasive in vivo mapping of brain functions in the human cortex
- 27 October 2026
- Published by Springer Nature in Communications Biology
Open AccessAutomated and noninvasive in vivo mapping of brain functions in the human cortex
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (5)
Correlation of blood biomarkers with microstructural brain injury in survivors of out-of-hospital cardiac arrest
In-hospital mortality among resuscitated out-of-hospital cardiac arrest (OHCA) patients remains high. Identifying patients who will benefit from intensive care while avoiding prolonged, potentially unnecessary treatments is essential. Blood-based biomarkers provide a novel method for evaluating brain injury. The ability of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), neuron-specific enolase (NSE) and total-tau (t-tau) to measure white and grey matter injury is unestablished in comatose OHCA survivors treated with targeted temperature management (TTM) or xenon combined with TTM. We examined correlations between the biomarkers and white and grey matter injury assessed with diffusion tensor imaging (DTI). This was a randomized, single-blind, phase 2 clinical drug trial involving two multipurpose intensive care units in Finland. It was conducted between August 2009 and March 2015. One hundred and ten comatose OHCA patients aged 24 to 76 years were randomly assigned to either inhaled xenon treatment combined with 24-h TTM (33°C) (n = 55, xenon group) or TTM alone (n = 55, control group). MRI data were available from 96 patients, with a median imaging time of 53 h (interquartile range, 47–64 h) after OHCA. Biomarker data were obtained from 105 patients. In the control group of 48 patients, after adjusting for age, sex and site, a disruption of white matter microintegrity as measured by decreased fractional anisotropy (FA) of DTI, the primary endpoint of the trial, showed a significant negative correlation with NfL at 24, 48 and 72 h (ρ = −0.28 to −0.37; P < 0.05), NSE at 48 and 72 h (ρ = −0.30 to −0.35; P < 0.05) and t-tau only at 72 h (ρ = −0.30; P < 0.05). In the xenon group (n = 48), these correlations were absent at all timepoints. The NfL–FA partial correlations showed progressive divergence between the xenon and control groups, with a statistically significant between-group difference observed at 72 h (ρ = −0.37 versus ρ = 0.14; P = 0.016). Cortical or basal ganglia grey matter mean diffusivity did not have a consistent correlation with biomarker levels at different time points. No statistically significant differences were found between the xenon and control groups in the adjusted geometric mean levels of GFAP, NfL, NSE or t-tau at various time points following OHCA. In conclusion, NfL correlated with FA in controls but not in the xenon group. This between-group difference reached significance at 72 h, suggesting that xenon may modify the relationship between axonal injury and white matter microstructure after OHCA.
- 1 September 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (5)
Open AccessCorrelation of blood biomarkers with microstructural brain injury in survivors of out-of-hospital cardiac arrest
In-hospital mortality among resuscitated out-of-hospital cardiac arrest (OHCA) patients remains high. Identifying patients who will benefit from intensive care while avoiding prolonged, potentially unnecessary treatments is essential. Blood-based biomarkers provide a novel method for evaluating brain injury. The ability of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), neuron-specific enolase (NSE) and total-tau (t-tau) to measure white and grey matter injury is unestablished in comatose OHCA survivors treated with targeted temperature management (TTM) or xenon combined with TTM. We examined correlations between the biomarkers and white and grey matter injury assessed with diffusion tensor imaging (DTI). This was a randomized, single-blind, phase 2 clinical drug trial involving two multipurpose intensive care units in Finland. It was conducted between August 2009 and March 2015. One hundred and ten comatose OHCA patients aged 24 to 76 years were randomly assigned to either inhaled xenon treatment combined with 24-h TTM (33°C) (n = 55, xenon group) or TTM alone (n = 55, control group). MRI data were available from 96 patients, with a median imaging time of 53 h (interquartile range, 47–64 h) after OHCA. Biomarker data were obtained from 105 patients. In the control group of 48 patients, after adjusting for age, sex and site, a disruption of white matter microintegrity as measured by decreased fractional anisotropy (FA) of DTI, the primary endpoint of the trial, showed a significant negative correlation with NfL at 24, 48 and 72 h (ρ = −0.28 to −0.37; P < 0.05), NSE at 48 and 72 h (ρ = −0.30 to −0.35; P < 0.05) and t-tau only at 72 h (ρ = −0.30; P < 0.05). In the xenon group (n = 48), these correlations were absent at all timepoints. The NfL–FA partial correlations showed progressive divergence between the xenon and control groups, with a statistically significant between-group difference observed at 72 h (ρ = −0.37 versus ρ = 0.14; P = 0.016). Cortical or basal ganglia grey matter mean diffusivity did not have a consistent correlation with biomarker levels at different time points. No statistically significant differences were found between the xenon and control groups in the adjusted geometric mean levels of GFAP, NfL, NSE or t-tau at various time points following OHCA. In conclusion, NfL correlated with FA in controls but not in the xenon group. This between-group difference reached significance at 72 h, suggesting that xenon may modify the relationship between axonal injury and white matter microstructure after OHCA.
- Open Access
Distinct cortical excitability and connectivity profiles within the human SMA complex
Introduction and aim: Understanding brain functions increasingly relies on a network-based perspective, emphasizing interactions across distributed regions. High-order cognitive functions, like language and executive processes, engage such networks rather than isolated cortical areas, yet mapping their dynamics in humans remains challenging. The supplementary motor area (SMA) complex serves as a crucial hub, functioning as an interface between cognitive and sensorimotor processing. Navigated transcranial magnetic stimulation combined with electroencephalography (TMS–EEG) enables causal, time-resolved assessment of cortical excitability and connectivity with high temporal and spatial precision. Extending prior proof-of-concept work, this study aims to provide normative neurophysiological signatures of the SMA complex (pre-SMA and SMA). Methods: Twenty-one healthy subjects underwent a TMS–EEG session where six stimulation targets over the SMA complex (three in pre-SMA, one in the border between pre-SMA and SMA, two in SMA) were recorded. Global cortical excitability via global mean field power (GMFP) was computed over three time-windows (10–50, 50–100, and 100–200 ms) and compared across targets. Normalized power in different frequency bands (α, β1, β2, γ) and natural frequency (NF) were also computed and compared across stimulation sites. Then, we calculated tractography-derived connectivity metrics to examine corticothalamic projections from each stimulation site. Apparent fiber density (AFD)-derived connection strength quantified intra-axonal fibre volume along pathways to the whole thalamus, whereas fibre bundle capacity (FBC) assessed the aggregate intra-axonal cross-sectional area at pathway endpoints, providing an estimate of information transmission capacity to each of the 23 thalamic nuclei. Results: Cortical excitability and oscillatory properties varied significantly across TMS targets. A gradient in cortical excitability was observed, where anterior and middle portions of pre-SMA exhibited significantly lower GMFP in the early post-stimulus phase (i.e., 10–50 ms) than SMA portions; interestingly, these differences were clearly dampened in a later time-window (50–100 ms) and disappeared after this period. Furthermore, higher α and lower β2 power were observed in anterior pre-SMA than posterior pre-SMA portions. No differences were observed in NF. Crucially, we also observed significant differences in whole- and single-nuclei thalamic structural connectivity. Discussion: These findings provide direct human in vivo evidence for distinct neurophysiological and structural connectivity profiles of the pre-SMA and SMA, possibly reflecting their different cytoarchitectonic, myeloarchitectonic and connectivity properties. Variations in cortical excitability, oscillatory dynamics, and FBC along the rostro-caudal axis may mirror functional specialization, with pre-SMA supporting cognitive control processes and SMA engaging motor-related thalamocortical networks. Together, the results demonstrate the sensitivity of TMS–EEG and diffusion-weighted connectomics to measure fine-grained neurophysiological differences of corticothalamic projections, which can lead to individualized neuromodulation targeting.
Open AccessDistinct cortical excitability and connectivity profiles within the human SMA complex
Introduction and aim: Understanding brain functions increasingly relies on a network-based perspective, emphasizing interactions across distributed regions. High-order cognitive functions, like language and executive processes, engage such networks rather than isolated cortical areas, yet mapping their dynamics in humans remains challenging. The supplementary motor area (SMA) complex serves as a crucial hub, functioning as an interface between cognitive and sensorimotor processing. Navigated transcranial magnetic stimulation combined with electroencephalography (TMS–EEG) enables causal, time-resolved assessment of cortical excitability and connectivity with high temporal and spatial precision. Extending prior proof-of-concept work, this study aims to provide normative neurophysiological signatures of the SMA complex (pre-SMA and SMA). Methods: Twenty-one healthy subjects underwent a TMS–EEG session where six stimulation targets over the SMA complex (three in pre-SMA, one in the border between pre-SMA and SMA, two in SMA) were recorded. Global cortical excitability via global mean field power (GMFP) was computed over three time-windows (10–50, 50–100, and 100–200 ms) and compared across targets. Normalized power in different frequency bands (α, β1, β2, γ) and natural frequency (NF) were also computed and compared across stimulation sites. Then, we calculated tractography-derived connectivity metrics to examine corticothalamic projections from each stimulation site. Apparent fiber density (AFD)-derived connection strength quantified intra-axonal fibre volume along pathways to the whole thalamus, whereas fibre bundle capacity (FBC) assessed the aggregate intra-axonal cross-sectional area at pathway endpoints, providing an estimate of information transmission capacity to each of the 23 thalamic nuclei. Results: Cortical excitability and oscillatory properties varied significantly across TMS targets. A gradient in cortical excitability was observed, where anterior and middle portions of pre-SMA exhibited significantly lower GMFP in the early post-stimulus phase (i.e., 10–50 ms) than SMA portions; interestingly, these differences were clearly dampened in a later time-window (50–100 ms) and disappeared after this period. Furthermore, higher α and lower β2 power were observed in anterior pre-SMA than posterior pre-SMA portions. No differences were observed in NF. Crucially, we also observed significant differences in whole- and single-nuclei thalamic structural connectivity. Discussion: These findings provide direct human in vivo evidence for distinct neurophysiological and structural connectivity profiles of the pre-SMA and SMA, possibly reflecting their different cytoarchitectonic, myeloarchitectonic and connectivity properties. Variations in cortical excitability, oscillatory dynamics, and FBC along the rostro-caudal axis may mirror functional specialization, with pre-SMA supporting cognitive control processes and SMA engaging motor-related thalamocortical networks. Together, the results demonstrate the sensitivity of TMS–EEG and diffusion-weighted connectomics to measure fine-grained neurophysiological differences of corticothalamic projections, which can lead to individualized neuromodulation targeting.
- Open Access
TMS–EEG-derived excitation/inhibition ratio as a diagnostic biomarker for major depressive disorder
Major depressive disorder (MDD) is characterized by both physiological and psychological changes that impact daily function and quality of life. Despite advancements in treatment approaches, clinical outcomes remain variable, highlighting the need for reliable biomarkers to guide treatment selection and to monitor treatment responses. Transcranial magnetic stimulation combined with electroencephalography (TMS–EEG) allows for the characterization of local cortical excitation and inhibition through TMS-evoked potentials (TEPs). However, interindividual variability and various artifacts have previously limited the utility of TEPs for biomarker development. We applied single-pulse TMS to the left dorsolateral prefrontal cortex (L-DLPFC), and recorded EEG responses in 28 individuals with MDD and 8 healthy controls. An individualized mapping procedure identified stimulation sites and intensities that minimized artifacts and ensured early TEP (p = 0.003), and correlated with depression symptom severity quantified with the Quick Inventory of Depressive Symptomatology Self-Report ( r = 0.459, p < 0.05), Ruminative Response Scale ( r = 0.656, p < 0.001), Patient Health Questionnaire ( r = 0.368, p < 0.05), and Positive Valence Systems Scale ( r = 0.332, p < 0.05). These correlations were not observed when an anatomy-based targeting method (Beam F3) was applied with the conventional stimulation intensity of 120% of the resting motor threshold. Our findings highlight the utility of a novel individualised mapping technique in capturing high-quality early TEPs through a real-time EEG readout for minimisation of artifacts and ensuring a minimum TMS-evoked response. The altered TEP peak ratio adds to the growing body of evidence that the excitation/inhibition imbalance plays a role in MDD neurophysiology and serves as a promising candidate biomarker that warrants further investigation.
Open AccessTMS–EEG-derived excitation/inhibition ratio as a diagnostic biomarker for major depressive disorder
Major depressive disorder (MDD) is characterized by both physiological and psychological changes that impact daily function and quality of life. Despite advancements in treatment approaches, clinical outcomes remain variable, highlighting the need for reliable biomarkers to guide treatment selection and to monitor treatment responses. Transcranial magnetic stimulation combined with electroencephalography (TMS–EEG) allows for the characterization of local cortical excitation and inhibition through TMS-evoked potentials (TEPs). However, interindividual variability and various artifacts have previously limited the utility of TEPs for biomarker development. We applied single-pulse TMS to the left dorsolateral prefrontal cortex (L-DLPFC), and recorded EEG responses in 28 individuals with MDD and 8 healthy controls. An individualized mapping procedure identified stimulation sites and intensities that minimized artifacts and ensured early TEP (p = 0.003), and correlated with depression symptom severity quantified with the Quick Inventory of Depressive Symptomatology Self-Report ( r = 0.459, p < 0.05), Ruminative Response Scale ( r = 0.656, p < 0.001), Patient Health Questionnaire ( r = 0.368, p < 0.05), and Positive Valence Systems Scale ( r = 0.332, p < 0.05). These correlations were not observed when an anatomy-based targeting method (Beam F3) was applied with the conventional stimulation intensity of 120% of the resting motor threshold. Our findings highlight the utility of a novel individualised mapping technique in capturing high-quality early TEPs through a real-time EEG readout for minimisation of artifacts and ensuring a minimum TMS-evoked response. The altered TEP peak ratio adds to the growing body of evidence that the excitation/inhibition imbalance plays a role in MDD neurophysiology and serves as a promising candidate biomarker that warrants further investigation.
- Open Access
- 31 October 2025
- Published by Elsevier in NeuroImage
- Vol. 322, 121553
Predictive modeling of TMS-evoked responses: Unraveling instantaneous excitability states
- 31 October 2025
- Published by Elsevier in NeuroImage
- Vol. 322, 121553
Open AccessPredictive modeling of TMS-evoked responses: Unraveling instantaneous excitability states
- Open Access
Fast and standardized motor-hotspot determination with automated TMS mapping
Determining the optimal stimulation target for motor responses (motor hotspot) and the required intensity for reliably eliciting said responses (motor threshold) are common procedures in transcranial magnetic stimulation (TMS) research and treatments. However, the procedures for determining them are user-dependent, slow, and lack standardization, leading to long stimulation sessions with potentially inadequate outcomes. Partially automated algorithms for determining the motor threshold have been developed, but the motor hotspot is still largely mapped by hand. Automating the hotspot mapping will accelerate the process and improve standardization and accuracy. We developed a fully automated algorithm for finding the motor hotspot with multi-locus TMS and Bayesian optimization. Tested online in five healthy participants, the algorithm located motor hotspots with (mean ± 95% CI) 2.1 ± 0.7 mm and 6 ± 2° difference from the global best target with only (mean) 47 stimuli. This is a significant improvement from previous motor-mapping algorithms, which do not optimize for stimulation location and orientation simultaneously. This accurate, fast, and user-independent procedure paves the way for faster experimental processes and more streamlined clinical applications.
Open AccessFast and standardized motor-hotspot determination with automated TMS mapping
Determining the optimal stimulation target for motor responses (motor hotspot) and the required intensity for reliably eliciting said responses (motor threshold) are common procedures in transcranial magnetic stimulation (TMS) research and treatments. However, the procedures for determining them are user-dependent, slow, and lack standardization, leading to long stimulation sessions with potentially inadequate outcomes. Partially automated algorithms for determining the motor threshold have been developed, but the motor hotspot is still largely mapped by hand. Automating the hotspot mapping will accelerate the process and improve standardization and accuracy. We developed a fully automated algorithm for finding the motor hotspot with multi-locus TMS and Bayesian optimization. Tested online in five healthy participants, the algorithm located motor hotspots with (mean ± 95% CI) 2.1 ± 0.7 mm and 6 ± 2° difference from the global best target with only (mean) 47 stimuli. This is a significant improvement from previous motor-mapping algorithms, which do not optimize for stimulation location and orientation simultaneously. This accurate, fast, and user-independent procedure paves the way for faster experimental processes and more streamlined clinical applications.
- 13 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e67339
Neuroimaging-Guided TMS–EEG for Real-Time Cortical Network Mapping
The cerebral cortex is organized into structurally and functionally segregated networks, enabling the human brain to process information highly efficiently. Transcranial magnetic stimulation (TMS), in combination with electroencephalography (EEG), offers a non-invasive approach to probing brain networks, revealing cortical excitability and causal connectivity. However, this method faces two significant challenges: (a) ensuring the quality of TMS-evoked potentials (TEPs) to maximize information gain, often requiring comprehensive cortical mapping, and (b) eliciting the response from the network of interest and not from adjacent cortical sites. Existing TMS targeting approaches frequently fail to precisely stimulate functionally relevant cortical areas, hindering treatment efficacy and the identification of biomarkers. The presented protocol integrates precise cortical mapping to acquire artifact-free TEPs, enabling reliable and reproducible measurements of early TEP components. This precision improves sensitivity to subtle neurophysiological variations and strengthens correlations with clinical phenotypes, supporting biomarker discovery in neuropsychiatric disorders. The proposed protocol utilizes structural, functional, and diffusion magnetic resonance imaging (MRI) to identify cortical patches belonging to the network of interest. Anatomical parcellation, functional connectivity, and real-time tractography are applied to locate areas with strong connectivity to other brain regions associated with the target network. The resulting personalized cortical clusters define the initial stimulation targets. TMS–EEG mapping is then employed to optimize TMS parameters by localizing cortical areas with high excitability, enhancing neuronal response magnitude while reducing non-neuronal noise, including muscle artifacts, decay, and other confounding factors affecting early TMS–EEG responses. A systematic exploration of the cortical mantle is conducted, adjusting stimulation location, orientation, and intensity, with continuous data quality monitoring through real-time visualization of averaged TEPs. TMS parameters producing artifact-free responses with clearly discernible early TEP components are selected for data collection. This article introduces the neuroimaging-guided TMS–EEG mapping technique and highlights the methodological advancements and benefits achievable through its application.
- 13 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e67339
Neuroimaging-Guided TMS–EEG for Real-Time Cortical Network Mapping
The cerebral cortex is organized into structurally and functionally segregated networks, enabling the human brain to process information highly efficiently. Transcranial magnetic stimulation (TMS), in combination with electroencephalography (EEG), offers a non-invasive approach to probing brain networks, revealing cortical excitability and causal connectivity. However, this method faces two significant challenges: (a) ensuring the quality of TMS-evoked potentials (TEPs) to maximize information gain, often requiring comprehensive cortical mapping, and (b) eliciting the response from the network of interest and not from adjacent cortical sites. Existing TMS targeting approaches frequently fail to precisely stimulate functionally relevant cortical areas, hindering treatment efficacy and the identification of biomarkers. The presented protocol integrates precise cortical mapping to acquire artifact-free TEPs, enabling reliable and reproducible measurements of early TEP components. This precision improves sensitivity to subtle neurophysiological variations and strengthens correlations with clinical phenotypes, supporting biomarker discovery in neuropsychiatric disorders. The proposed protocol utilizes structural, functional, and diffusion magnetic resonance imaging (MRI) to identify cortical patches belonging to the network of interest. Anatomical parcellation, functional connectivity, and real-time tractography are applied to locate areas with strong connectivity to other brain regions associated with the target network. The resulting personalized cortical clusters define the initial stimulation targets. TMS–EEG mapping is then employed to optimize TMS parameters by localizing cortical areas with high excitability, enhancing neuronal response magnitude while reducing non-neuronal noise, including muscle artifacts, decay, and other confounding factors affecting early TMS–EEG responses. A systematic exploration of the cortical mantle is conducted, adjusting stimulation location, orientation, and intensity, with continuous data quality monitoring through real-time visualization of averaged TEPs. TMS parameters producing artifact-free responses with clearly discernible early TEP components are selected for data collection. This article introduces the neuroimaging-guided TMS–EEG mapping technique and highlights the methodological advancements and benefits achievable through its application.
- 13 June 2025
- Published by MyJove Corporation
- No. 220,p. e67339
JoVE Video Dataset
The cerebral cortex is organized into structurally and functionally segregated networks, enabling the human brain to process information highly efficiently. Transcranial magnetic stimulation (TMS), in combination with electroencephalography (EEG), offers a non-invasive approach to probing brain networks, revealing cortical excitability and causal connectivity. However, this method faces two significant challenges: (a) ensuring the quality of TMS-evoked potentials (TEPs) to maximize information gain, often requiring comprehensive cortical mapping, and (b) eliciting the response from the network of interest and not from adjacent cortical sites. Existing TMS targeting approaches frequently fail to precisely stimulate functionally relevant cortical areas, hindering treatment efficacy and the identification of biomarkers. The presented protocol integrates precise cortical mapping to acquire artifact-free TEPs, enabling reliable and reproducible measurements of early TEP components. This precision improves sensitivity to subtle neurophysiological variations and strengthens correlations with clinical phenotypes, supporting biomarker discovery in neuropsychiatric disorders. The proposed protocol utilizes structural, functional, and diffusion magnetic resonance imaging (MRI) to identify cortical patches belonging to the network of interest. Anatomical parcellation, functional connectivity, and real-time tractography are applied to locate areas with strong connectivity to other brain regions associated with the target network. The resulting personalized cortical clusters define the initial stimulation targets. TMS–EEG mapping is then employed to optimize TMS parameters by localizing cortical areas with high excitability, enhancing neuronal response magnitude while reducing non-neuronal noise, including muscle artifacts, decay, and other confounding factors affecting early TMS–EEG responses. A systematic exploration of the cortical mantle is conducted, adjusting stimulation location, orientation, and intensity, with continuous data quality monitoring through real-time visualization of averaged TEPs. TMS parameters producing artifact-free responses with clearly discernible early TEP components are selected for data collection. This article introduces the neuroimaging-guided TMS–EEG mapping technique and highlights the methodological advancements and benefits achievable through its application.
- 13 June 2025
- Published by MyJove Corporation
- No. 220,p. e67339
JoVE Video Dataset
The cerebral cortex is organized into structurally and functionally segregated networks, enabling the human brain to process information highly efficiently. Transcranial magnetic stimulation (TMS), in combination with electroencephalography (EEG), offers a non-invasive approach to probing brain networks, revealing cortical excitability and causal connectivity. However, this method faces two significant challenges: (a) ensuring the quality of TMS-evoked potentials (TEPs) to maximize information gain, often requiring comprehensive cortical mapping, and (b) eliciting the response from the network of interest and not from adjacent cortical sites. Existing TMS targeting approaches frequently fail to precisely stimulate functionally relevant cortical areas, hindering treatment efficacy and the identification of biomarkers. The presented protocol integrates precise cortical mapping to acquire artifact-free TEPs, enabling reliable and reproducible measurements of early TEP components. This precision improves sensitivity to subtle neurophysiological variations and strengthens correlations with clinical phenotypes, supporting biomarker discovery in neuropsychiatric disorders. The proposed protocol utilizes structural, functional, and diffusion magnetic resonance imaging (MRI) to identify cortical patches belonging to the network of interest. Anatomical parcellation, functional connectivity, and real-time tractography are applied to locate areas with strong connectivity to other brain regions associated with the target network. The resulting personalized cortical clusters define the initial stimulation targets. TMS–EEG mapping is then employed to optimize TMS parameters by localizing cortical areas with high excitability, enhancing neuronal response magnitude while reducing non-neuronal noise, including muscle artifacts, decay, and other confounding factors affecting early TMS–EEG responses. A systematic exploration of the cortical mantle is conducted, adjusting stimulation location, orientation, and intensity, with continuous data quality monitoring through real-time visualization of averaged TEPs. TMS parameters producing artifact-free responses with clearly discernible early TEP components are selected for data collection. This article introduces the neuroimaging-guided TMS–EEG mapping technique and highlights the methodological advancements and benefits achievable through its application.
- Open Access
NeuroSimo: an open-source software for closed-loop EEG- or EMG-guided TMS
Objective Our goal was to create open-source software for closed-loop EEG–TMS that allows researchers to rapidly prototype and develop novel stimulation paradigms in a high-level programming language. This addresses the limitations of current solutions, which often rely on proprietary hardware and software, limiting their accessibility and customizability, or comprise ad-hoc pipelines tailored to specific use cases. Approach We developed NeuroSimo, a software platform that enables arbitrary EEG–TMS stimulation protocols written in Python, leveraging Python’s ecosystem of scientific, neuroimaging, and machine learning libraries. The core software is written in C++ with an embedded Python interpreter and employs the Robot Operating System (ROS 2) for inter-process communication. NeuroSimo runs on real-time-enabled Linux Ubuntu, using LabJack T4 for pulse triggering, and supports two EEG device models (Bittium NeurOne, BrainProducts actiCHamp) and TMS devices that deliver pulses via trigger signals. The software includes a graphical user interface for configuration and performance monitoring, and supports GPU processing for neural network computations. Main results In brain-state-dependent stimulation using the Phastimate algorithm, which targets TMS pulses to the trough of sensorimotor μ-rhythm, NeuroSimo achieved a median timing error of 0.2 ms (95% CI: 0.2–0.2 ms), a 99th-percentile of 0.6 ms (0.6–0.6 ms), and a maximum of 1.4 ms. Significance As an open-source platform combining Python’s flexibility with real-time closed-loop EEG– TMS, NeuroSimo enables researchers to develop and implement novel therapeutic approaches, marking a significant advance in personalized brain stimulation.
Open AccessNeuroSimo: an open-source software for closed-loop EEG- or EMG-guided TMS
Objective Our goal was to create open-source software for closed-loop EEG–TMS that allows researchers to rapidly prototype and develop novel stimulation paradigms in a high-level programming language. This addresses the limitations of current solutions, which often rely on proprietary hardware and software, limiting their accessibility and customizability, or comprise ad-hoc pipelines tailored to specific use cases. Approach We developed NeuroSimo, a software platform that enables arbitrary EEG–TMS stimulation protocols written in Python, leveraging Python’s ecosystem of scientific, neuroimaging, and machine learning libraries. The core software is written in C++ with an embedded Python interpreter and employs the Robot Operating System (ROS 2) for inter-process communication. NeuroSimo runs on real-time-enabled Linux Ubuntu, using LabJack T4 for pulse triggering, and supports two EEG device models (Bittium NeurOne, BrainProducts actiCHamp) and TMS devices that deliver pulses via trigger signals. The software includes a graphical user interface for configuration and performance monitoring, and supports GPU processing for neural network computations. Main results In brain-state-dependent stimulation using the Phastimate algorithm, which targets TMS pulses to the trough of sensorimotor μ-rhythm, NeuroSimo achieved a median timing error of 0.2 ms (95% CI: 0.2–0.2 ms), a 99th-percentile of 0.6 ms (0.6–0.6 ms), and a maximum of 1.4 ms. Significance As an open-source platform combining Python’s flexibility with real-time closed-loop EEG– TMS, NeuroSimo enables researchers to develop and implement novel therapeutic approaches, marking a significant advance in personalized brain stimulation.
- Open Access
A High-Precision Timing Method and Digital Interface for Closed-Loop TMS
Objective Current transcranial magnetic stimulation (TMS) protocols exhibit high inter-subject variability in treatment outcomes, highlighting the need for personalized, brain-state-dependent closed-loop stimulation protocols. To enable such protocols, we aim to provide robust, precisely timed external control of TMS, with stimulation timed relative to feedback signals such as the electroencephalogram (EEG). Approach Commercial TMS devices typically rely on trigger signals for precise external pulse timing, while adjusting stimulation parameters, such as intensity, is better handled via serial digital communication, which supports robust error detection and feedback. However, combining these communication methods is inherently complex and prone to timing issues, such as race conditions. Furthermore, trigger signals lack capabilities essential for real-time systems, such as preventing late pulse delivery. We present a method for precise and accurate pulse timing, implemented through a digital interface that uses exclusively serial digital messaging, eliminating the need for trigger signals. This interface enables external control of pulse timing, intensity, and other parameters. The TMS device maintains its own internal clock and delivers pulses at pre-scheduled times, decoupling timing precision from the control device. Additionally, we propose a method for synchronizing such time-tracking TMS devices with commercial EEG systems, enabling precisely timed EEG–TMS. Main results Using these methods, our custom TMS device delivered pulses precisely aligned to the EEG signal, with timing errors consistently below 0.3 ms. These errors were constrained by the experimental setup, including the sampling rate of our EEG device and the signal-to-noise ratio affecting pulse detection. Significance Our timing method achieves sub-millisecond precision in brain-state-dependent closed-loop EEG–TMS, providing a foundation for robust TMS timing that supports adaptive, personalized stimulation protocols. The digital control interface, co-designed with our TMS device, integrates pulse timing and parameters, setting a precedent for future advancements in computer-controlled TMS.
Open AccessA High-Precision Timing Method and Digital Interface for Closed-Loop TMS
Objective Current transcranial magnetic stimulation (TMS) protocols exhibit high inter-subject variability in treatment outcomes, highlighting the need for personalized, brain-state-dependent closed-loop stimulation protocols. To enable such protocols, we aim to provide robust, precisely timed external control of TMS, with stimulation timed relative to feedback signals such as the electroencephalogram (EEG). Approach Commercial TMS devices typically rely on trigger signals for precise external pulse timing, while adjusting stimulation parameters, such as intensity, is better handled via serial digital communication, which supports robust error detection and feedback. However, combining these communication methods is inherently complex and prone to timing issues, such as race conditions. Furthermore, trigger signals lack capabilities essential for real-time systems, such as preventing late pulse delivery. We present a method for precise and accurate pulse timing, implemented through a digital interface that uses exclusively serial digital messaging, eliminating the need for trigger signals. This interface enables external control of pulse timing, intensity, and other parameters. The TMS device maintains its own internal clock and delivers pulses at pre-scheduled times, decoupling timing precision from the control device. Additionally, we propose a method for synchronizing such time-tracking TMS devices with commercial EEG systems, enabling precisely timed EEG–TMS. Main results Using these methods, our custom TMS device delivered pulses precisely aligned to the EEG signal, with timing errors consistently below 0.3 ms. These errors were constrained by the experimental setup, including the sampling rate of our EEG device and the signal-to-noise ratio affecting pulse detection. Significance Our timing method achieves sub-millisecond precision in brain-state-dependent closed-loop EEG–TMS, providing a foundation for robust TMS timing that supports adaptive, personalized stimulation protocols. The digital control interface, co-designed with our TMS device, integrates pulse timing and parameters, setting a precedent for future advancements in computer-controlled TMS.